Ovarian Neoplasms: all 2,759 studies
Page 19 of 28. Open to participants first (736), then studies with results posted, then the rest; newest registration first within each.
- Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)CompletedNCT03505307
- Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant ChemotherapyCompletedNCT03491033
- Natera Ovarian Cancer Detection AssayTerminatedNCT03485651
- Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in IndiaCompletedNCT03471572
- Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian CarcinomaCompletedNCT03470805Phase 2
- Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.Status unknownNCT03467178Phase 2
- Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III StudyCompletedNCT03464201Phase 2
- Sentinel Lymph Node in Early Ovarian CancerCompletedNCT03452982Phase 2
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingNCT03449108Phase 2
- Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian CancerStatus unknownNCT03448354Not applicable
- An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian CancerStatus unknownNCT03446495
- The Use of International Ovarian Tumor Analysis and Assessment of Adnexal Neoplasia in Differentiating Malignant and Benign Adnexal MassesStatus unknownNCT03442881
- Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian CancerCompletedNCT03430518Phase 1
- A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian CancerWithdrawnNCT03400306Phase 1
- Clinical Impact of Dedicated MR Staging of Ovarian CancerStatus unknownNCT03399344Not applicable
- A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)CompletedNCT03398655Phase 3
- A Study of Apatinib Treatment in for Advanced Ovarian CancerStatus unknownNCT03393507Phase 2
- Pelvic Microbiomes of Benign and Malignant Ovarian DiseasesStatus unknownNCT03388996
- The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.CompletedNCT03384511Phase 4
- IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOCCompletedNCT03378297Early Phase 1
- Debulking Surgery in Ovarian CancerCompletedNCT03378128Not applicable
- Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive SurgeryStatus unknownNCT03373058Phase 3
- Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian CancerStatus unknownNCT03371693Phase 3
- The Treatment Preferences of Women Diagnosed With Ovarian CancerCompletedNCT03367260
- Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian CancerCompletedNCT03367182
- BEACON - ABC in Recurrent Platinum Resistant HGSOCActive, not recruitingNCT03363867Phase 2
- Engineered Immune Effectors Against Ovarian CancerTerminatedNCT03362606Phase 1/2
- BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasActive, not recruitingNCT03355976Phase 2
- Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian CancerCompletedNCT03353831Phase 3
- Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer PatientsTerminatedNCT03342417Phase 2
- Self-Advocacy Serious Game in Advanced CancerCompletedNCT03339765Not applicable
- Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian CancerStatus unknownNCT03335241Phase 2
- Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine CancerCompletedNCT03325634Phase 1
- Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer PatientsCompletedNCT03324945Not applicable
- Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer PatientsStatus unknownNCT03321188Phase 2
- Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian CarcinomaStatus unknownNCT03302884Not applicable
- Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT03298074Phase 2
- Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian CancerCompletedNCT03297489Early Phase 1
- Risk-Reducing Surgeries for Hereditary Ovarian CancerStatus unknownNCT03294343Not applicable
- A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast CancerTerminatedNCT03292172Phase 1
- Survival Outcomes of Ovarian Malignancies in Chinese PopulationStatus unknownNCT03291262
- A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian CancerWithdrawnNCT03281681Phase 1/2
- Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer PatientsStatus unknownNCT03278717Phase 3
- Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerTerminatedNCT03277482Phase 1
- PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .CompletedNCT03275506Phase 2
- Evolution of the Therapeutic Care in Ovarian Cancer From 2011SuspendedNCT03275298
- Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT StudyCompletedNCT03270995Not applicable
- The INFLUENCE of Cytoreduction on PRO in EOCActive, not recruitingNCT03268876
- Trial in Patients With Relapsed Ovarian CancerCompletedNCT03267589Phase 2
- Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian CancerStatus unknownNCT03262545Phase 2
- Immunotherapy With Neo-adjuvant Chemotherapy for OVarian CancerCompletedNCT03249142Phase 1/2
- Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.Active, not recruitingNCT03246841Not applicable
- Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian CancerStatus unknownNCT03235648Not applicable
- Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCACompletedNCT03229122
- Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® TechnologyStatus unknownNCT03219242Not applicable
- Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant ChemotherapyCompletedNCT03206645Phase 1
- AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasCompletedNCT03205176Phase 1
- China Ovarian Cancer BRCA Testing StudyTerminatedNCT03203993
- Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor MalignanciesCompletedNCT03199586Phase 1
- Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer SurvivorsCompletedNCT03198286Not applicable
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2
- Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the PelvisCompletedNCT03193671
- Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid TumorsTerminatedNCT03189108
- Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian CancerStatus unknownNCT03188159Phase 2
- Genetically Modified T Cells Against Ovarian CancerTerminatedNCT03184753Phase 1/2
- Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian CancerStatus unknownNCT03180177Phase 3
- Gynacological Imaging Reporting and Data System in Ovarian Masses by UltrasonographyCompletedNCT03175991
- Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1
- Phase Ib Study of Chiauranib in Patients With Ovarian CancerCompletedNCT03166891Phase 1/2
- The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian CancerTerminatedNCT03162562Phase 1
- Resistant Ovarian Cancer, Olaparib and Liposomal DoxorubicinCompletedNCT03161132Phase 2
- Homologous Recombination Inquiry Through Ovarian Malignancy InvestigationsCompletedNCT03159572
- Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.CompletedNCT03155451
- EDMONd - Elemental Diet in Bowel ObstructionStatus unknownNCT03150992Not applicable
- Biomarkers for Early Detection of Ovarian Cancer Using Uterine LavageStatus unknownNCT03150121Not applicable
- An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesTerminatedNCT03144661Phase 1
- Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)CompletedNCT03133286
- Early Dehiscence Markers in Ovarian Cancer SurgeryCompletedNCT03131492
- Long Term Survivors in Ovarian CancerTerminatedNCT03128294
- Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian CancerCompletedNCT03126812Phase 1/2
- Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype FamiliesCompletedNCT03119285
- Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian CancerCompletedNCT03117933Phase 2
- Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian CancersStatus unknownNCT03112733
- Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf RegionCompletedNCT03082976
- A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian CancerCompletedNCT03081702Phase 1/2
- Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.Approved for marketingNCT03079687
- A Study Evaluating MM-310 in Patients With Solid TumorsStatus unknownNCT03076372Phase 1
- Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian CancerCompletedNCT03075540Not applicable
- A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsCompletedNCT03075462Phase 1
- A Trial of Fast Access to Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian CancerCompletedNCT03069872Not applicable
- Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in JapanNo longer availableNCT03063710
- Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT03056833Phase 1
- Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian CancerCompletedNCT03055143Phase 1
- Hysterectomy and OPPortunistic SAlpingectomyActive, not recruitingNCT03045965Not applicable
- Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingNCT03029403Phase 2
- Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian CancerCompletedNCT03028519Early Phase 1
- Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight LossCompletedNCT03027479Not applicable
- Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian CancerApproved for marketingNCT03025867
- The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer PatientsStatus unknownNCT03019315
- Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03017131Phase 1